Positive Results of Serum Galactomannan Assays and Pulmonary Computed Tomography Predict the Higher Response Rate of Empirical Antifungal Therapy in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 5, 2011, Pages 759-764

  Ji, Yu ^a   Xu, Lan ping ^a   Liu, Dai hong ^a   Chen, Yu hong ^a   Han, Wei ^a   Zhang, Xiao hui ^a   Chen, Huan ^a   Wang, Yu ^a   Wang, Jing zhi ^a   Liu, Kai yan ^a   Huang, Xiao jun ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

Allogeneic hematopoietic stem cell transplant; Empirical antifungal therapy; Galactomannan; Invasive aspergillosis

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; FLUCONAZOLE; GALACTOMANNAN; ITRACONAZOLE; VORICONAZOLE;

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBIOTIC THERAPY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CHILD; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FEVER; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; RECURRENT DISEASE; SCHOOL CHILD; SERODIAGNOSIS; SYSTEMIC MYCOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; LUNG; MALE; MANNANS; PREDICTIVE VALUE OF TESTS; TOMOGRAPHY, X-RAY COMPUTED; TRANSPLANTATION, HOMOLOGOUS;

EID: 79954619510     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.11.002     Document Type: Article

References (27)

1. Singh N. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 2001, 33:1692-1696.
2. Kojima R., Kami M., Nannya Y., et al. Incidence of invasive aspergillosis after allogeneic hematopoietic stem cell transplantation with a reduced-intensity regimen compared with transplantation with a conventional regimen. Biol Blood Marrow Transplant 2004, 10:645-652.
3. Singh N., Paterson D.L. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005, 18:44-69.
4. Marr K.A., Carter R.A., Crippa F., et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002, 34:909-917.
5. Upton A., Kirby K.A., Carpenter P., et al. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007, 44:531-540.
6. Segal B.H., Almyroudis N.G., Battiwalla M., et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis 2007, 44:402-409.
7. Walsh T.J., Anaissie E.J., Denning D.W., et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008, 46:327-360.
8. Boogaerts M., Winston D.J., Bow E.J., et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 2001, 135:412-422.
9. Rieger C.T., Ostermann H. Empiric vs. preemptive antifungal treatment: an appraisal of treatment strategies in haematological patients. Mycoses 2008, 51(Suppl 1):31-34.
10. Mahfouz T., Anaissie E. Prevention of fungal infections in the immunocompromised host. Curr Opin Invest Drugs 2003, 4:974-990.
11. Caillot D., Couaillier J.F., Bernard A., et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001, 19:253-259.
12. Greene R.E., Schlamm H.T., Oestmann J.W., et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007, 44:373-379.
13. Mennink-Kersten M.A., Donnelly J.P., Verweij P.E. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004, 4:349-357.
14. Marr K.A., Balajee S.A., McLaughin L., et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004, 190:641-649.
15. Pfeiffer C.D., Fine J.P., Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006, 42:1417-1427.
16. Maertens J., Theunissen K., Verhoef G., et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005, 41:1242-1250.
17. Cordonnier C., Pautas C., Maury S., et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009, 48:1042-1051.
18. Tomblyn M., Chiller T., Einsele H., et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009, 15:1143-1238.
19. Xu L.P., Tang F.F., Liu D.H., et al. [Secondary prophylaxis of invasive fungal infection in haematopoietic stem cell recipients]. Zhonghua Nei Ke Za Zhi 2009, 48:853-856.
20. Jun H.X., Zhixiang S., Chun W., et al. Clinical guidelines for the management of cancer patients with neutropenia and unexplained fever. Int J Antimicrob Agents 2005, 26(Suppl 2):S128-S132.
21. De Pauw B., Walsh T.J., Donnelly J.P., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813-1821.
22. Ji Y., Liu D.H., Xu L.P., et al. [The value of serum galactomannan detection for diagnosis of invasive aspergillosis in hematopoietic stem cell transplant recipients]. Zhonghua Xue Ye Xue Za Zhi 2007, 28:83-86.
23. Machetti M., Furfaro E., Viscoli C. Galactomannan in piperacillin-tazobactam: how much and to what extent?. Antimicrob Agents Chemother 2005, 49:3984-3985.
24. Kontoyiannis D.P., Marr K.A., Park B.J., et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010, 50:1091-1100.
25. Foy P.C., van Burik J.A., Weisdorf D.J. Galactomannan antigen enzyme-linked immunosorbent assay for diagnosis of invasive aspergillosis after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:440-443.
26. Kojima R., Tateishi U., Kami M., et al. Chest computed tomography of late invasive aspergillosis after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005, 11:506-511.
27. Walsh T.J., Finberg R.W., Arndt C., et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999, 340:764-771.